Phase 3 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have fully understood the study details and risks, and have agreed to take part by signing a consent form
- Men aged 18 or older
- People who have been confirmed through tissue testing to have a type of prostate cancer called prostate adenocarcinoma, and who have already received treatment for it
- People where prostate cancer is suspected to have come back or spread, based on rising PSA blood test results after surgery or radiation therapy (specific PSA level thresholds apply — confirm with trial site)
- People who are willing to undergo a biopsy, further surgery, or radiation therapy if the treating doctor recommends it
- People with an ECOG performance score of 0 or 2, which is a measure of how much cancer affects daily functioning (confirm with trial site)
- People whose blood counts, kidney function, and liver function fall within certain acceptable ranges as measured by blood tests
- People who are expected to live for at least 6 months
- People who agree to use effective contraception and avoid sperm donation from the time of signing the consent form until 3 months after receiving the study drug
Who may not be able to join:
- People who are currently in another interventional clinical trial, or who have recently taken an investigational drug and have not yet passed the required washout period, or who have taken part in a radioactive drug trial discontinued less than 3 months before signing the consent form
- People who have received an iodinated contrast dye injection within the past 24 hours, or certain high-density oral contrast agents (such as barium sulfate) within the past 5 days, before the study drug is given
- People who have received certain high-energy radioactive substances within a specific period before the study drug is given (confirm timeframe with trial site)
- People who were previously receiving hormone therapy (ADT) for prostate cancer, unless it was stopped at least 16 weeks before the study drug is given
- People where the treating doctor determines that a medical condition or other factor could affect their safety or ability to participate in the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 13602883007
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The Positive Predictive Value of 18F-Florastamin PET/CT in patients with suspected recurrence of prostate cancer on a patient-level.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.